PLx Pharma Inc.
PLXP · NASDAQ
9/30/2022 | 6/30/2022 | 3/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -20.1% | -76.8% | 30.8% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | -$0 | -$0 | $0 | $0 |
| % Margin | -278.2% | -69.8% | 43.9% | 44% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Income | -$0 | -$0 | -$0 | $0 |
| % Margin | -2,808% | -3,009.9% | -873.5% | 223.8% |
| Other Income/Exp. Net | $0 | $0 | $0 | $0 |
| Pre-Tax Income | -$0 | -$0 | -$0 | $0 |
| Tax Expense | -$0 | -$0 | -$0 | $0 |
| Net Income | -$0 | -$0 | -$0 | $0 |
| % Margin | -1,594.6% | -1,900.2% | -162% | 223.8% |
| EPS | -0.22 | -0.33 | -0.12 | 0.13 |
| % Growth | 33.3% | -175% | -192.3% | – |
| EPS Diluted | -0.22 | -0.33 | -0.12 | 0.13 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | -$0 |
| Depreciation & Amortization | -$0 | -$0 | -$0 | $0 |
| EBITDA | -$0 | -$0 | -$0 | $0 |
| % Margin | -3,368.9% | -3,548.7% | -1,226.5% | 227.2% |